SCHEMBL2497204

SCHEMBL2497204

COc1ccc(C(=O)Nc2ccc(Cl)c(C(=O)Nc3cnc(Nc4ccc(S(=O)(=O)C5CCNCC5)cc4)nc3)c2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BTK Q06187 6/20 0.46
▸ CSF1R P07333 1/20 0.46
▸ BLK P51451 2/20 0.45
▸ LCK P06239 3/20 0.44
▸ KDR P35968 3/20 0.44
▸ MAPK14 Q16539 2/20 0.44
▸ KMT2A Q03164 3/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ SYK P43405 1/20 0.43
▸ SRC P12931 2/20 0.42
▸ ABL1 P00519 1/20 0.42
▸ YES1 P07947 1/20 0.42
▸ PDGFRB P09619 1/20 0.42
▸ AURKA O14965 2/20 0.42
▸ BRAF P15056 2/20 0.42
▸ MEN1 O00255 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14304344 0.90 BTK (0.54) BTKCSF1RBLKLCKKDR
SCHEMBL2498581 0.89 BTK (0.47) BTKLCKKDRMAPK14SRC
SCHEMBL2495433 0.88 BTK (0.47) BTKCSF1RLCKKDRMAPK14
SCHEMBL12190173 0.88 BTK (0.46) BTKCSF1RBLKLCKKDR
SCHEMBL2497569 0.86 BTK (0.54) BTKCSF1RLCKMAPK14PDGFRB
SCHEMBL2497284 0.85 NAMPT (0.47) BTKBLKLCKKDRMAPK14
SCHEMBL2498477 0.85 BTK (0.46) BTKLCKKDRMAPK14KMT2A
SCHEMBL2497186 0.84 BTK (0.68) BTKCSF1RBLKLCKKDR
SCHEMBL2498483 0.83 BTK (0.51) BTKBLKLCKKDRSRC
SCHEMBL12190172 0.82 BTK (0.45) BTKLCKKDRMAPK14KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 — — US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 — — US disclosed
US-8030487-B2 2-amino—5-substituted pyrimidine inhibitors TARGEGEN, INC. (US) 2011-10-04 — — US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 — — US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 — — US disclosed
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-31 — — US disclosed
WO-2008008234-A1 2-AMINO-5-SUBSTITUTED PYRIMIDINE INHIBITORS TARGEGEN, INC. (US) 2008-01-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027070-A1 2-AMINO--5-SUBSTITUTED PYRIMIDINE INHIBITORS KDR, FLT4, FLT1 BTK 44/4885CSF1R 575/4885BLK 71/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback